Phaseline

Companies › TRYP Therapeutics

TRYP Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRP-8802
Psilocybin; serotonin 5-HT2A receptor agonist
HTR2APhase 2Irritable Bowel Syndrome–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06206265TRP-8802Phase 2Irritable Bowel SyndromeGastroenterologyMar 2026

Targets

HTR2A (1)

Companies with the same targets

Cybin IRL COMPASS Pathways ACADIA Pharmaceuticals Vanda Pharmaceuticals Intra-Cellular Therapies Definium Therapeutics US Sichuan Kelun Pharmaceutical Boryung Pharmaceutical Otsuka NeuroRx

Companies built like this

NorthSea Therapeutics Healthgen Biotechnology Dr. Falk Pharma Napo Therapeutics Panafina

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.